Yang et al. demonstrated that the HDAC6/let-7i-5p/TSP1 axis reduced the neoplastic and antiphagocytic properties of HCC cells by targeting CD47, providing a promising therapeutic target for the treatment of HCC 106. The gene discussed is HDAC6; the disease is hepatocellular carcinoma.